Lipid nanoparticles to counteract gastric infection without affecting gut microbiota

• Type: Article in International Scientific Journal
• Date: 2018

Authors

Seabra, CL (Author) Other; Nunes, C (Author) Other; Bras, M (Author) Other; Gomez Lazaro, M (Author) Other; Celso Reis (Author) ICBAS; Goncalves, IC (Author) Other; Salette Reis (Author) FFUP; Martins, MCL (Author) Other

Journal

Title: European Journal of Pharmaceutics and Biopharmaceutics

Vol. 127

Pages: 378-386

ISSN: 0939-6411

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 15 Citations

Scopus - 15 Citations

Other information

Authenticus ID: P-00N-S0R

DOI: 10.1016/j.ejpb.2018.02.030

Abstract (EN): Helicobacter pylori infection is one of the major risk factors for gastric cancer development. Available antibiotic-based treatments not only fail in around 20% of patients but also have a severe negative impact on the gut microbiota. Recently, we demonstrated that nanostructured lipid carriers (NLC), even without any drug loaded, are bactericidal against H. pylori at low concentrations. This work aims to clarify NLC mode of action and to evaluate if their bactericidal effect is specific to H. pylori without affecting bacteria from microbiota. NLC were produced by hot homogenization followed by ultrasonication method, using Precirol (R) ATO5 and Miglyol (R) 812 as lipids and Tween (R) 60 as a surfactant. NLC were able to eradicate H. pylori without affecting the other tested bacteria (Lactobacillus, E. coli, S. epidermidis and S. aureus). Bioimaging assays demonstrated that NLC rapidly bind to and cross the H. pylori bacterial membrane, destabilizing and disrupting it, which leads to leakage of the cytoplasmic contents and consequent bacterial death. In an era where efficient alternatives to antibiotics are urgent, NLC are an interesting route to be explored in the quest for new antibiotic-free therapies to fight H. pylori infection.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9